Stock, pipeline and biotech catalyst intelligence
Reported statements
| USD | 2026 |
|---|---|
| Revenue | $31.7M |
| R&D expense | $30.7M |
| Operating income | −$51.0M |
| Net income | −$62.8M |
| Cash & equivalents | $258.6M |
| Total debt | $252.1M |
| Operating cash flow | −$43.0M |
| Free cash flow | −$43.2M |
Company profile
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.